Over the past 30 years, 18,000 clinical trials that have been registered in Australia, with the sector contributing $1.4 billion to Australia’s economy annually. Trials are a critical aspect of evidence-based medicine, and are essential for testing how new treatments, tests and vaccines will work. In New Zealand they contribute $146 million to the New Zealand economy.
Australia and New Zealand have established themselves as ideal locations to host clinical trials due to their diverse participant populations, sophisticated healthcare and research environments as well as government backed support. Both countries have adopted the International Council for Harmonisation (ICH) Guideline for Good Clinical Practice (GCP) to ensure all trials collect high quality and credible data that is internationally recognised.
To capitalise on this unique position and growth, a coordinated multi-site clinical research operation was missing.
Now, three of the largest clinical trial organisations across Australia and New Zealand have united to form Momentum Clinical Research – an end-to-end clinical research network with sites that have been operating for over 20 years. Combined, they have 13 site locations across the Trans-Tasman and are set to open more locations to allow more studies to take place and enable everyday people to access new and emerging therapies.
In February 2024, New Zealand’s renowned P3 Research joined forces with Australia’s AusTrials and Holdsworth House to form Momentum Clinical Research. The combined entity can now provide sponsors a single point of contact for their current 13 sites across the two countries,
Momentum Clinical Research aims to provide quick responses to feasibility requests, faster study starts and accelerated recruitment – all leading to the delivery of high-quality results for Phase 1b-IV clinical trials. Momentum Clinical Research has become the only Trans-Tasman network of clinical trial sites.
Australian Health Journal spoke with Aus Trials Research Director, Dr Munro Neville, on the Australian clinical trial landscape more broadly and reasons for creating a Trans-Tasman clinical research organisation.
Further growth in the industry is expected, with the Australian Government having pledged $750 million to increase clinical trial activity between 2022-2032. Similarly, the New Zealand Government has invested $98 million into health research funding from 2017-2027 to facilitate the conduct of clinical trials.
-
Allied Health Leader shares career insights
Mirella Vagnarelli is a distinguished healthcare leader with proven expertise across South Australia and the United Kingdom, where she has successfully led large, multidisciplinary teams. Holding a Master of Business Administration (Health) from Flinders University, she earned Fellowship status with the Australasian College of Health Service Management in 2022. In 2023, Mirella was honoured as a scholarship recipient for the prestigious ‘Women in Leadership’ Program at the Monash Centre for Health Research and Implementation.
-
Allied health flourishes in regional and rural Victoria
Associate Professor Sanjay Jeganathan, Chair of the Council of Presidents of Medical Colleges (CPMC) states, ”Our rural and regional communities deserve the same access to specialist care as our cities. We’re seeing real results from our colleges’ commitment to rural training.”
-
Improvements in dental literacy and greater clinical insights through digital technology
Dr. Kenneth Soh is a General Dentist based in Kellyville, New South Wales, a suburb located in northwestern Sydney. Originally from Melbourne, he studied Bachelor of Dental Science (BDSc) at Melbourne University and graduated in 2003. After working for a year in the Mornington Peninsula, Dr. Soh moved to New South Wales, initially thinking it would be temporary; however, he has been there for 19 years. While he has considered specialising, he finds joy in all aspects of dentistry.
